ABSTRACT

Introduction: Sensitization to human leukocyte antigens has long posed an obstacle to organ transplantation. With desensitization protocol refinement, new drug development, and organ allocation policy changes, access to transplant for sensitized patients has never been greater. Yet in spite of these advances the problem of donor-specific antibody remains incompletely solved, and many patients remain poorly served by the therapies that do exist.

Area covered: Imlifidase is a new drug with a mechanism of action that enables it to transiently yet efficiently eliminate donor-specific antibody over a much more rapid time course than any heretofore existing therapy. This unique property suggests that imlifidase may have far-reaching potential for patients in whom donor-specific antibodies may preclude successful transplantation. Below follows a review of the clinical experience with imlifidase to date as well as a discussion of the transplant applications that eagerly await the availability of this novel agent.

Expert opinion: Imlifidase is a first-in-class pharmaceutical agent that safely and efficiently cleaves IgG, and holds promise to be a game-changer for sensitized patients in need of lifesaving organ transplants.

摘要

简介：对人类白细胞抗原的敏感性长期以来一直是器官移植的障碍。随着脱敏方案的改进、新药开发和器官分配政策的变化，致敏患者获得移植的机会从未如此多。然而，尽管取得了这些进展，供体特异性抗体的问题仍未完全解决，许多患者仍然无法接受现有的疗法。

涵盖领域：Imlifidase 是一种新药，其作用机制使其能够在比任何现有疗法都快得多的时间过程中瞬时而有效地消除供体特异性抗体。这种独特的特性表明，imlifidase 可能对供体特异性抗体可能妨碍成功移植的患者具有深远的潜力。下面是对迄今为止 imlifidase 临床经验的回顾，以及对急切等待这种新型药物上市的移植应用的讨论。

专家意见：Imlifidase 是一种一流的药剂，可以安全有效地切割 IgG，有望成为需要挽救生命的器官移植的敏感患者的游戏规则改变者。